Abstract: A refrigeration cycle apparatus includes a compressor, a first heat exchanger, a second heat exchanger, a third heat exchanger, a flow path switching valve, a first expansion valve, a second expansion valve, a third expansion valve, a refrigerant container, a first check valve, and a second check valve. The flow path switching valve switches a circulation direction of a non-azeotropic refrigerant mixture between a first circulation direction and a second circulation direction. A first port of the third expansion valve communicates with the refrigerant container through the third heat exchanger. A second port of the third expansion valve communicates through the first check valve with a first flow path between the first heat exchanger and the first expansion valve, and communicates through the second check valve with a second flow path between the second heat exchanger and the second expansion valve.

Abstract: A laminated body contains a first metal layer containing copper and a second metal layer containing nickel and directly laminated on the first metal layer. A full width at half maximum of an X-ray diffraction peak having the maximum intensity among at least one X-ray diffraction peak derived from a nickel-containing crystal in the second metal layer is 0.3° or more and 1.2° or less.

Abstract: A sheet processor subjecting a sheet having been conveyed forward to processing along a direction perpendicular to a conveyance direction of the sheet, includes: a processing unit performing the processing; and a receiving unit receiving the processing unit therein in a state capable of perfecting the processing on the sheet, and the processing unit includes a first processing tool 4A and a second processing tool 4B disposed to vertically oppose each other with a conveyance surface of the sheet disposed therebetween, and the receiving unit includes at least one receiver that removably receives the first processing tool 4A and the second processing tool 4B in the state capable of performing the processing on the sheet, with arbitrarily selected one of the first processing tool 4A and the second processing tool 4B disposed above the conveyance surface, and with arbitrarily selected another of the first processing tool 4A and the second processing tool 4B disposed below the conveyance surface.

Abstract: A sheet processor subjecting a sheet having been conveyed forward to processing along a direction perpendicular to a conveyance direction of the sheet, includes: a processing unit performing the processing; and a receiving unit receiving the processing unit therein in a state capable of perfecting the processing on the sheet, and the processing unit includes a first processing tool 4A and a second processing tool 4B disposed to vertically oppose each other with a conveyance surface of the sheet disposed therebetween, and the receiving unit includes at least one receiver that removably receives the first processing tool 4A and the second processing tool 4B in the state capable of performing the processing on the sheet, with arbitrarily selected one of the first processing tool 4A and the second processing tool 4B disposed above the conveyance surface, and with arbitrarily selected another of the first processing tool 4A and the second processing tool 4B disposed below the conveyance surface.

Abstract: The invention provides a compound effective as an antitumor active agent or vaccine adjuvant and an intermediate useful for the synthesis of the compound, as well as production methods thereof, and a medicament containing the novel compound. The compound is a carbamate glycolipid represented by the formula (I) wherein each symbol is as defined herein. The invention also provides a dendritic cell pulsed with the glycolipid.

Abstract: The invention provides a compound represented by the formula (I) wherein R1 is a hydrogen atom or a hydroxyl group; two R2 are the same or different and each is a hydrogen atom or a hydroxyl group; R3 is a hydrocarbon group having 8-14 carbon atoms, which optionally has substituent(s); and R4 is a hydrocarbon group having 18-24 carbon atoms, which optionally has substituent(s), or a salt thereof. The invention also provides a method of treating an autoimmune disease or suppressing immunity by administering the aforementioned compound or a salt thereof to a patient in need thereof.

Abstract: The invention provides a compound represented by the formula (I) wherein R1 is a hydrogen atom or a hydroxyl group; two R2 are the same or different and each is a hydrogen atom or a hydroxyl group; R3 is a hydrocarbon group having 8-14 carbon atoms, which optionally has substituent(s); and R4 is a hydrocarbon group having 18-24 carbon atoms, which optionally has substituent(s), or a salt thereof. The invention also provides a method of treating an autoimmune disease or suppressing immunity by administering the aforementioned compound or a salt thereof to a patient in need thereof.

Abstract: The invention provides a compound effective as an antitumor active agent or vaccine adjuvant and an intermediate useful for the synthesis of the compound, as well as production methods thereof, and a medicament containing the novel compound. The compound is a carbamate glycolipid represented by the formula (I) wherein each symbol is as defined herein. The invention also provides a dendritic cell pulsed with the glycolipid.

Abstract: A compound represented by the following formula (1): wherein R1 is an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, R2 is a C1-26 hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom or a C1-26 hydrocarbon group optionally having substituent(s), R4 is a C1-21 hydrocarbon group optionally having substituent(s), X is an oxygen atom or —CH2—, and Y is —CH2—, —CH(OH)— or —CH?CH—, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-? of NKT cells.

Abstract: The invention provides esterified ?-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein R1 is a hydrocarbon group having a carbon number of 1 to 30, R2 is a hydrocarbon group having a carbon number of 1 to 20, R3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R4 and R5 are the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or R4 and R5 in combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.

Abstract: The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like.

Abstract: A compound represented by the following formula (1): wherein R1 is an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, R2 is a C1-26 hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom or a C1-26 hydrocarbon group optionally having substituent(s), R4 is a C1-21 hydrocarbon group optionally having substituent(s), X is an oxygen atom or —CH2—, and Y is —CH2—, —CH(OH)— or —CH?CH—, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-? of NKT cells.

Abstract: The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.

Abstract: The present invention relates to a compound represented by the following formula (1?) wherein R is an aldopyranose residue, R2 is a C2-18 hydrocarbon group optionally having substituent(s), R3 is an acyl group, X is an oxygen atom, a sulfur atom or —NH—, and p is an integer of 0-4, or a salt thereof. The compound of the present invention has a specific immunoregulatory ability, and is useful for the prophylaxis or treatment of autoimmune diseases and the like.

Abstract: The present invention provide a compound represented by the following formula (1) wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention and a salt thereof can preferentially induce production of IL-4, which is one kind of cytokines that control action of immunocytes. Therefore, it is useful for the prophylaxis or treatment of autoimmune diseases, infectious diseases and the like, and prophylaxis or treatment of diseases caused by functional promotion of Th1 cells.

Abstract: The invention provides esterified ?-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein R1 is a hydrocarbon group having a carbon number of 1 to 30, R2 is a hydrocarbon group having a carbon number of 1 to 20, R3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R4 and R5 are the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or R4 and R5 in combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.

Abstract: The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like.

Abstract: The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.

Abstract: The present invention provide a compound represented by the following formula (1) wherein each symbol is as defined in the specification, or a salt thereof. The compound of the present invention and a salt thereof can preferentially induce production of IL-4, which is one kind of cytokines that control action of immunocytes. Therefore, it is useful for the prophylaxis or treatment of autoimmune diseases, infectious diseases and the like, and prophylaxis or treatment of diseases caused by functional promotion of Th1 cells.

Abstract: The present invention provides a nasal vaccine capable of intranasally inducing an effective immunity reaction. Specifically, the invention provides a nasal vaccine containing a compound having an NKT cell-activating action, particularly a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a compound represented by the formula (II): wherein each symbol is as defined in the specification, and an immunogen in an amount effective for stimulating an immune response.